Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort

Objectives - Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical microbiology and infection 2023-02, Vol.29 (2), p.254.e7-254.e13
Hauptverfasser: Ghosn, Jade, Bachelet, Delphine, Livrozet, Marine, Cervantes-Gonzalez, Minerva, Poissy, Julien, Goehringer, François, Gandonniere, Charlotte Salmon, Maillet, Mylène, Bani-Sadr, Firouzé, Martin-Blondel, Guillaume, Tattevin, Pierre, Launay, Odile, Surgers, Laure, Dudoignon, Emmanuel, Liegeon, Geoffroy, Zucman, David, Joseph, Cédric, Senneville, Eric, Yelnik, Cécile, Roger, Pierre-Marie, Faure, Karine, Gousseff, Marie, Cabié, André, Duval, Xavier, Chirouze, Catherine, Laouénan, Cedric
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 254.e13
container_issue 2
container_start_page 254.e7
container_title Clinical microbiology and infection
container_volume 29
creator Ghosn, Jade
Bachelet, Delphine
Livrozet, Marine
Cervantes-Gonzalez, Minerva
Poissy, Julien
Goehringer, François
Gandonniere, Charlotte Salmon
Maillet, Mylène
Bani-Sadr, Firouzé
Martin-Blondel, Guillaume
Tattevin, Pierre
Launay, Odile
Surgers, Laure
Dudoignon, Emmanuel
Liegeon, Geoffroy
Zucman, David
Joseph, Cédric
Senneville, Eric
Yelnik, Cécile
Roger, Pierre-Marie
Faure, Karine
Gousseff, Marie
Cabié, André
Duval, Xavier
Chirouze, Catherine
Laouénan, Cedric
description Objectives - Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort. Methods - Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender. Results - We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale
doi_str_mv 10.1016/j.cmi.2022.08.028
format Article
fullrecord <record><control><sourceid>hal</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03801797v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_03801797v1</sourcerecordid><originalsourceid>FETCH-hal_primary_oai_HAL_hal_03801797v13</originalsourceid><addsrcrecordid>eNqVTctKw0AUHUSx9fEB7u7WReJMEvJwV6pthYrBFnEXrumNnTKZCTPTlnyXP2gK_oCrczhPxu4EDwUX6cMurFsZRjyKQp6HPMrP2FgkaRHwtBDnAxdFHmRJ_DliV87tOOdRHCeXbBSnohB5ko3ZT2npgIp0TWAaKI3zwaTee4Lp28fLUyAKWPVt503rYH0kdSB4NdpvHWDjycLCuE56VNKhl0aD1FCi9bKWHWrv4J08Sk2bkzEzSpljsO8eYaJR9Y4crLwdio0cEl89zElvhtHGmhYQlmi_CUo7XFDt5XA9NVtj_Q27aFA5uv3Da3Y_e15PF8EWVdVZ2aLtK4OyWkyW1Unjcc5FVmQHEf8n-wsqa29q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Ghosn, Jade ; Bachelet, Delphine ; Livrozet, Marine ; Cervantes-Gonzalez, Minerva ; Poissy, Julien ; Goehringer, François ; Gandonniere, Charlotte Salmon ; Maillet, Mylène ; Bani-Sadr, Firouzé ; Martin-Blondel, Guillaume ; Tattevin, Pierre ; Launay, Odile ; Surgers, Laure ; Dudoignon, Emmanuel ; Liegeon, Geoffroy ; Zucman, David ; Joseph, Cédric ; Senneville, Eric ; Yelnik, Cécile ; Roger, Pierre-Marie ; Faure, Karine ; Gousseff, Marie ; Cabié, André ; Duval, Xavier ; Chirouze, Catherine ; Laouénan, Cedric</creator><creatorcontrib>Ghosn, Jade ; Bachelet, Delphine ; Livrozet, Marine ; Cervantes-Gonzalez, Minerva ; Poissy, Julien ; Goehringer, François ; Gandonniere, Charlotte Salmon ; Maillet, Mylène ; Bani-Sadr, Firouzé ; Martin-Blondel, Guillaume ; Tattevin, Pierre ; Launay, Odile ; Surgers, Laure ; Dudoignon, Emmanuel ; Liegeon, Geoffroy ; Zucman, David ; Joseph, Cédric ; Senneville, Eric ; Yelnik, Cécile ; Roger, Pierre-Marie ; Faure, Karine ; Gousseff, Marie ; Cabié, André ; Duval, Xavier ; Chirouze, Catherine ; Laouénan, Cedric</creatorcontrib><description>Objectives - Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort. Methods - Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender. Results - We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale &lt;57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%). Conclusions - One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1016/j.cmi.2022.08.028</identifier><identifier>PMID: 36191847</identifier><language>eng</language><publisher>Elsevier for the European Society of Clinical Microbiology and Infectious Diseases</publisher><subject>Human health and pathology ; Life Sciences</subject><ispartof>Clinical microbiology and infection, 2023-02, Vol.29 (2), p.254.e7-254.e13</ispartof><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-6150-2376 ; 0000-0003-1878-9858 ; 0000-0002-8363-7028 ; 0000-0002-8363-7028 ; 0000-0002-6150-2376 ; 0000-0003-1878-9858</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://u-picardie.hal.science/hal-03801797$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghosn, Jade</creatorcontrib><creatorcontrib>Bachelet, Delphine</creatorcontrib><creatorcontrib>Livrozet, Marine</creatorcontrib><creatorcontrib>Cervantes-Gonzalez, Minerva</creatorcontrib><creatorcontrib>Poissy, Julien</creatorcontrib><creatorcontrib>Goehringer, François</creatorcontrib><creatorcontrib>Gandonniere, Charlotte Salmon</creatorcontrib><creatorcontrib>Maillet, Mylène</creatorcontrib><creatorcontrib>Bani-Sadr, Firouzé</creatorcontrib><creatorcontrib>Martin-Blondel, Guillaume</creatorcontrib><creatorcontrib>Tattevin, Pierre</creatorcontrib><creatorcontrib>Launay, Odile</creatorcontrib><creatorcontrib>Surgers, Laure</creatorcontrib><creatorcontrib>Dudoignon, Emmanuel</creatorcontrib><creatorcontrib>Liegeon, Geoffroy</creatorcontrib><creatorcontrib>Zucman, David</creatorcontrib><creatorcontrib>Joseph, Cédric</creatorcontrib><creatorcontrib>Senneville, Eric</creatorcontrib><creatorcontrib>Yelnik, Cécile</creatorcontrib><creatorcontrib>Roger, Pierre-Marie</creatorcontrib><creatorcontrib>Faure, Karine</creatorcontrib><creatorcontrib>Gousseff, Marie</creatorcontrib><creatorcontrib>Cabié, André</creatorcontrib><creatorcontrib>Duval, Xavier</creatorcontrib><creatorcontrib>Chirouze, Catherine</creatorcontrib><creatorcontrib>Laouénan, Cedric</creatorcontrib><title>Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort</title><title>Clinical microbiology and infection</title><description>Objectives - Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort. Methods - Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender. Results - We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale &lt;57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%). Conclusions - One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men.</description><subject>Human health and pathology</subject><subject>Life Sciences</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqVTctKw0AUHUSx9fEB7u7WReJMEvJwV6pthYrBFnEXrumNnTKZCTPTlnyXP2gK_oCrczhPxu4EDwUX6cMurFsZRjyKQp6HPMrP2FgkaRHwtBDnAxdFHmRJ_DliV87tOOdRHCeXbBSnohB5ko3ZT2npgIp0TWAaKI3zwaTee4Lp28fLUyAKWPVt503rYH0kdSB4NdpvHWDjycLCuE56VNKhl0aD1FCi9bKWHWrv4J08Sk2bkzEzSpljsO8eYaJR9Y4crLwdio0cEl89zElvhtHGmhYQlmi_CUo7XFDt5XA9NVtj_Q27aFA5uv3Da3Y_e15PF8EWVdVZ2aLtK4OyWkyW1Unjcc5FVmQHEf8n-wsqa29q</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Ghosn, Jade</creator><creator>Bachelet, Delphine</creator><creator>Livrozet, Marine</creator><creator>Cervantes-Gonzalez, Minerva</creator><creator>Poissy, Julien</creator><creator>Goehringer, François</creator><creator>Gandonniere, Charlotte Salmon</creator><creator>Maillet, Mylène</creator><creator>Bani-Sadr, Firouzé</creator><creator>Martin-Blondel, Guillaume</creator><creator>Tattevin, Pierre</creator><creator>Launay, Odile</creator><creator>Surgers, Laure</creator><creator>Dudoignon, Emmanuel</creator><creator>Liegeon, Geoffroy</creator><creator>Zucman, David</creator><creator>Joseph, Cédric</creator><creator>Senneville, Eric</creator><creator>Yelnik, Cécile</creator><creator>Roger, Pierre-Marie</creator><creator>Faure, Karine</creator><creator>Gousseff, Marie</creator><creator>Cabié, André</creator><creator>Duval, Xavier</creator><creator>Chirouze, Catherine</creator><creator>Laouénan, Cedric</creator><general>Elsevier for the European Society of Clinical Microbiology and Infectious Diseases</general><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-1878-9858</orcidid><orcidid>https://orcid.org/0000-0002-8363-7028</orcidid><orcidid>https://orcid.org/0000-0002-8363-7028</orcidid><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-1878-9858</orcidid></search><sort><creationdate>202302</creationdate><title>Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort</title><author>Ghosn, Jade ; Bachelet, Delphine ; Livrozet, Marine ; Cervantes-Gonzalez, Minerva ; Poissy, Julien ; Goehringer, François ; Gandonniere, Charlotte Salmon ; Maillet, Mylène ; Bani-Sadr, Firouzé ; Martin-Blondel, Guillaume ; Tattevin, Pierre ; Launay, Odile ; Surgers, Laure ; Dudoignon, Emmanuel ; Liegeon, Geoffroy ; Zucman, David ; Joseph, Cédric ; Senneville, Eric ; Yelnik, Cécile ; Roger, Pierre-Marie ; Faure, Karine ; Gousseff, Marie ; Cabié, André ; Duval, Xavier ; Chirouze, Catherine ; Laouénan, Cedric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hal_primary_oai_HAL_hal_03801797v13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Human health and pathology</topic><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghosn, Jade</creatorcontrib><creatorcontrib>Bachelet, Delphine</creatorcontrib><creatorcontrib>Livrozet, Marine</creatorcontrib><creatorcontrib>Cervantes-Gonzalez, Minerva</creatorcontrib><creatorcontrib>Poissy, Julien</creatorcontrib><creatorcontrib>Goehringer, François</creatorcontrib><creatorcontrib>Gandonniere, Charlotte Salmon</creatorcontrib><creatorcontrib>Maillet, Mylène</creatorcontrib><creatorcontrib>Bani-Sadr, Firouzé</creatorcontrib><creatorcontrib>Martin-Blondel, Guillaume</creatorcontrib><creatorcontrib>Tattevin, Pierre</creatorcontrib><creatorcontrib>Launay, Odile</creatorcontrib><creatorcontrib>Surgers, Laure</creatorcontrib><creatorcontrib>Dudoignon, Emmanuel</creatorcontrib><creatorcontrib>Liegeon, Geoffroy</creatorcontrib><creatorcontrib>Zucman, David</creatorcontrib><creatorcontrib>Joseph, Cédric</creatorcontrib><creatorcontrib>Senneville, Eric</creatorcontrib><creatorcontrib>Yelnik, Cécile</creatorcontrib><creatorcontrib>Roger, Pierre-Marie</creatorcontrib><creatorcontrib>Faure, Karine</creatorcontrib><creatorcontrib>Gousseff, Marie</creatorcontrib><creatorcontrib>Cabié, André</creatorcontrib><creatorcontrib>Duval, Xavier</creatorcontrib><creatorcontrib>Chirouze, Catherine</creatorcontrib><creatorcontrib>Laouénan, Cedric</creatorcontrib><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghosn, Jade</au><au>Bachelet, Delphine</au><au>Livrozet, Marine</au><au>Cervantes-Gonzalez, Minerva</au><au>Poissy, Julien</au><au>Goehringer, François</au><au>Gandonniere, Charlotte Salmon</au><au>Maillet, Mylène</au><au>Bani-Sadr, Firouzé</au><au>Martin-Blondel, Guillaume</au><au>Tattevin, Pierre</au><au>Launay, Odile</au><au>Surgers, Laure</au><au>Dudoignon, Emmanuel</au><au>Liegeon, Geoffroy</au><au>Zucman, David</au><au>Joseph, Cédric</au><au>Senneville, Eric</au><au>Yelnik, Cécile</au><au>Roger, Pierre-Marie</au><au>Faure, Karine</au><au>Gousseff, Marie</au><au>Cabié, André</au><au>Duval, Xavier</au><au>Chirouze, Catherine</au><au>Laouénan, Cedric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort</atitle><jtitle>Clinical microbiology and infection</jtitle><date>2023-02</date><risdate>2023</risdate><volume>29</volume><issue>2</issue><spage>254.e7</spage><epage>254.e13</epage><pages>254.e7-254.e13</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>Objectives - Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort. Methods - Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender. Results - We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale &lt;57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%). Conclusions - One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men.</abstract><pub>Elsevier for the European Society of Clinical Microbiology and Infectious Diseases</pub><pmid>36191847</pmid><doi>10.1016/j.cmi.2022.08.028</doi><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-1878-9858</orcidid><orcidid>https://orcid.org/0000-0002-8363-7028</orcidid><orcidid>https://orcid.org/0000-0002-8363-7028</orcidid><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-1878-9858</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1198-743X
ispartof Clinical microbiology and infection, 2023-02, Vol.29 (2), p.254.e7-254.e13
issn 1198-743X
1469-0691
language eng
recordid cdi_hal_primary_oai_HAL_hal_03801797v1
source Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Human health and pathology
Life Sciences
title Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T23%3A28%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20Post-Acute%20COVID-19%20Symptoms%20Twelve%20Months%20after%20Hospitalisation%20in%20Participants%20Retained%20in%20Follow-up:%20Analyses%20Stratified%20by%20Gender%20from%20a%20Large%20Prospective%20Cohort&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Ghosn,%20Jade&rft.date=2023-02&rft.volume=29&rft.issue=2&rft.spage=254.e7&rft.epage=254.e13&rft.pages=254.e7-254.e13&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1016/j.cmi.2022.08.028&rft_dat=%3Chal%3Eoai_HAL_hal_03801797v1%3C/hal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36191847&rfr_iscdi=true